​
​

Inozyme Pharma Stock (NASDAQ:INZY)

ForecastRevenueOwnershipFinancialsChart
Inozyme Pharma by TradingView

Previous Close

$5.62

52W Range

$2.69 - $7.79

50D Avg

$5.14

200D Avg

$5.01

Market Cap

$376.41M

Avg Vol (3M)

$305.24K

Beta

1.52

Div Yield

-

INZY Company Profile

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

59

IPO Date

Jul 24, 2020

Website

INZY Performance

INZY Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-75.64M$-68.67M$-56.65M
Net Income$-71.17M$-65.45M$-56.41M
EBITDA$-74.35M$-68.67M$-55.97M
Basic EPS$-1.37$-1.73$-2.39
Diluted EPS$-1.37$-1.73$-2.39

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
XFORX4 Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
DAWNDay One Biopharmaceuticals, Inc.
PDSBPDS Biotechnology Corporation
HOOKHOOKIPA Pharma Inc.
TERNTerns Pharmaceuticals, Inc.
ELDNEledon Pharmaceuticals, Inc.
ABOSAcumen Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals, Inc.